Transplanting Hepatitis C Positive Organs
Hepatitis C, Awaiting Organ Transplant
About this trial
This is an interventional treatment trial for Hepatitis C
Eligibility Criteria
Inclusion Criteria:
- Men and women who are age ≥ 18 years
- Active on either the cardiac, lung, or kidney transplant waiting list
- Willing and able to provide written informed consent to receive organs from an increased risk donor with a known transmissible infection
Exclusion Criteria:
- Hepatitis B NAT or viral load positive
- Evidence of cirrhosis or clinically significant liver disease
Sites / Locations
- Brigham and Women's HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
HCV NAT Positive Donor
HCV NAT Negative, HCV Ab Positive Donor
Intervention: 2 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily Participants who receive allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant.
Intervention: HCV viral load monitoring Participants who receive allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops.